Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 928

Sort by

Sort Order Select

Journal Articles

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Diana Hanekamp, Lok Lam Ngai, Jeroen J. W. M. Janssen, Arjan van de Loosdrecht, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2021) 137 (12): 1694–1697.

https://doi.org/10.1182/blood.2020007150

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

How I diagnose and treat NPM1 -mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Blood (2021) 137 (5): 589–599.

https://doi.org/10.1182/blood.2020008211

Published: 2021

Journal Articles

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Robert P. Hasserjian, David P. Steensma, Timothy A. Graubert, Benjamin L. Ebert

Blood (2020) 135 (20): 1729–1738.

https://doi.org/10.1182/blood.2019004770

Published: 2020

Journal Articles

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Alexandros Spyridonidis

Blood (2020) 135 (19): 1639–1649.

https://doi.org/10.1182/blood.2019003566

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3888.

https://doi.org/10.1182/blood-2019-125165

Published: 2019

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 5491.

https://doi.org/10.1182/blood-2019-131730

Published: 2019

Journal Articles

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Jayant Narang, MD, Surabhi Bajpai, MD, Rudresh Rajnikant Jarecha, MBBS, MD, Sayali Karve, PhD, Katarina Ludajic, PhD, Manish Sharma, MD, Shweta Narang, MD, Michael O'Connor, PhD

Blood (2019) 134 (Supplement_1): 5277.

https://doi.org/10.1182/blood-2019-130570

Published: 2019

Journal Articles

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Anna Vanazzi, MD, Safaa Ramadan, PhD MD, Francesca De Lorenzi, MD, Paola Arena, MD, Enrico Derenzini, MD PhD, Mario Rietjens, Anna Rotili, MD, Antuono Latronico, MD, Laura Travaini, MD, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, MD, Valentina Tabanelli, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5283.

https://doi.org/10.1182/blood-2019-125239

Published: 2019

Journal Articles

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Silvia Mangiacavalli, Zacchino Michela, MD, Virginia Valeria Ferretti, Claudio Salvatore Cartia, MD, Giovanni Savietto, MD, Pietro Benvenuti, MD, Marzia Varettoni, Sara Rattotti, Brociner Marco, Gabriele Merati, MD, Luca Arcaini

Blood (2019) 134 (Supplement_1): 5495.

https://doi.org/10.1182/blood-2019-126422

Published: 2019

Journal Articles

Can Peri-Transplant Radiation Therapy Improve Outcomes of Autologous Stem Cell Transplant in Hodgkin Lymphoma?

Harsh Shah, DO, Paramveer Singh, MD, Jorgena Kosti, DO, Hyejeong Jang, Seongho Kim, PhD, Andrew Kin, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 5702.

https://doi.org/10.1182/blood-2019-124931

Published: 2019

Journal Articles

Is There Any Impact of Uric Acid Levels during the Peri-Transplant Period on Acute Graft Vs. Host Disease Incidence and Allotransplant Outcome?

Panayotis Kaloyannidis, Hussin Alsubaie, MD, Rawan Omari, MD, Solaf Kanfar, MD, Zahra Abdrabalamir Alshammasi, MD, Mohammed Darweesh, MD, Enas Mutahar, MD, Kenana Ajlan, Technician, Abdulhamid Liacini, Norah Muhlem, Technician, Ahmed Bahrani, MD, Afra Dayel, MD, John Apostolidis, MD, Hani Al Hashmi, MD, Khalid Ahmed Al-Anazi, MD

Blood (2019) 134 (Supplement_1): 5681.

https://doi.org/10.1182/blood-2019-128651

Published: 2019

Journal Articles

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

Liliana Raquel Loureiro, PhD, Anja Feldmann, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Stefanie Koristka, PhD, Nicola Mitwasi, Anja Hoffmann, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD, Claudia Arndt, PhD

Blood (2019) 134 (Supplement_1): 5613.

https://doi.org/10.1182/blood-2019-128249

Published: 2019

Journal Articles

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Cassidy Brothers, MD MSC

Blood (2019) 134 (Supplement_1): 5631.

https://doi.org/10.1182/blood-2019-125378

Published: 2019

Journal Articles

High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)

Alexander R. Vartanov, MD, Stacey M. Fernandes, BS, Winnie I Nguy, Danielle M. Brander, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Allison P. Jacob, Jon E. Arnason, MD, Jeremy S. Abramson, MD MMSc, Matthew S. Davids, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 4291.

https://doi.org/10.1182/blood-2019-124305

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

DARTs point the way forward in AML

How I diagnose and treat NPM1 -mutated AML

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Can Peri-Transplant Radiation Therapy Improve Outcomes of Autologous Stem Cell Transplant in Hodgkin Lymphoma?

Is There Any Impact of Uric Acid Levels during the Peri-Transplant Period on Acute Graft Vs. Host Disease Incidence and Allotransplant Outcome?

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only